Condensed Consolidated Statement of Equity (USD $) In Thousands, except Share data, unless otherwise specified	Total		OPKO Uruguay Ltda.	Inspiro	OPKO Health Europe	OPKO Brazil	OPKO Renal	OPKO Biologics	OPKO Lab	Common Stock	Common Stock OPKO Health Europe	Common Stock OPKO Brazil	Common Stock OPKO Renal	Common Stock OPKO Biologics	Common Stock OPKO Lab	Treasury	Treasury OPKO Uruguay Ltda.	Treasury Inspiro	Treasury OPKO Health Europe	Additional Paid-In Capital	Additional Paid-In Capital OPKO Uruguay Ltda.	Additional Paid-In Capital Inspiro	Additional Paid-In Capital OPKO Health Europe	Additional Paid-In Capital OPKO Brazil	Additional Paid-In Capital OPKO Renal	Additional Paid-In Capital OPKO Biologics	Additional Paid-In Capital OPKO Lab	Accumulated Other Comprehensive Income	Accumulated Deficit	Noncontrolling Interests	Series D Preferred Stock	Series D Preferred Stock Common Stock	Series D Preferred Stock Additional Paid-In Capital	Notes	Notes Common Stock	Notes Additional Paid-In Capital
Beginning balance at Dec. 31, 2011	$ 160,882									$ 2,975						$ (8,092)				$ 524,814								$ 907	$ (359,722)	$ 0
Beginning balance, shares at Dec. 31, 2011										297,503,033						(2,488,477)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	5,131																			5,131
Exercise of Common Stock options	2,234									10										2,224
Exercise of Common Stock options, shares										1,019,967
Exercise of Common Stock warrants	45									1										44
Exercise of Common Stock warrants, shares										65,015
Adjustment of Common Stock Value	0									(1)										1
Adjustment of Common Stock Shares										(100,000)
Issuance of Common Stock in connection with acquisition					805				32,888						71				635				170				32,817
Issuance of Common Stock in connection with acquisition, shares															7,072,748				195,421
Net loss attributable to common shareholders	(29,048)																												(29,048)
Net loss attributable to noncontrolling interests	(492)																													(492)
Other comprehensive loss	6,449																											6,449
Ending balance at Dec. 31, 2012	178,894									3,056						(7,457)				565,201								7,356	(388,770)	(492)
Ending balance, shares at Dec. 31, 2012										305,560,763						(2,293,056)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	10,983																			10,983
Exercise of Common Stock options	22,796									92										22,704
Exercise of Common Stock options, shares										9,244,971
Exercise of Common Stock warrants	628									15										613
Exercise of Common Stock warrants, shares										1,487,774
Preferred Stock dividend																															(3,015)		(3,015)
Conversion of Preferred Stock																															24,386	113	24,273	20,839	24	20,815
Conversion of Preferred Stock, shares																																11,290,320			2,396,145
Issuance of Common Stock in connection with acquisition						435	146,902	586,643				1	205	637										434	146,697	586,006
Issuance of Common Stock in connection with acquisition, shares												64,684	20,517,030	63,670,805
Stock Issued During Period, Value, Deferred Payment					4,435						5												4,430
Stock Issued During Period, Share, Contingent Consideration																			28,993
Stock Issued During Period, Value, Contingent Consideration					337														95				242
Stock Issued During Period, Share, Deferred Payment, shares											585,703
Net loss attributable to common shareholders	(114,407)																												(114,407)
Net loss attributable to noncontrolling interests	(2,939)																													(2,939)
Other comprehensive loss	(3,938)																											(3,938)
Ending balance at Dec. 31, 2013	872,979	[1]								4,148						(7,362)				1,379,383								3,418	(503,177)	(3,431)
Ending balance, shares at Dec. 31, 2013										414,818,195						(2,264,063)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	14,737																			14,737
Exercise of Common Stock options	5,915									23										5,892
Exercise of Common Stock options, shares	2,723,666									2,328,947
Exercise of Common Stock warrants	7,013									31										6,982
Exercise of Common Stock warrants, shares										3,063,894
Issuance of Common Stock in connection with acquisition	95,665		159	8,566						110			22				61	3,250		95,555	98	5,316
Issuance of Common Stock in connection with acquisition, shares										10,974,431			2,236,210				19,140	999,556
Stock Issued During Period, Value, Contingent Consideration							21,155																		21,133
Net loss attributable to common shareholders	(171,666)																												(171,666)
Net loss attributable to noncontrolling interests	(2,972)																													(2,972)
Other comprehensive loss	(15,810)																											(15,810)
Ending balance at Dec. 31, 2014	$ 835,741	[1]								$ 4,334						$ (4,051)				$ 1,529,096								$ (12,392)	$ (674,843)	$ (6,403)
Ending balance, shares at Dec. 31, 2014										433,421,677						(1,245,367)

[1] As of December 31, 2014 and December 31, 2013, total assets include $7.6 million and $6.7 million, respectively, and total liabilities include $12.1 million and $10.4 million, respectively, related to SciVac, previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 4.